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 In the United States, colorectal cancer serves as the third most 
commonly occurring cancer1. Approximately 143,000 new cases of 
colorectal cancer will be diagnosed this year in the United States, and about 
51,000 of those cases will be fatalities1. 
If colorectal cancer is detected before stage III, the 5-year survival 
rate is almost 70%4. Previous research has shown that colorectal cancer 
development is a multistep process that evolves through a diverse molecular 
mechanism that can go undetected until metastasis occurs, which is often too 
late4. It is very important to identify the early genetic and molecular 
alterations that cause cancerous tumor cells to target specific organs. It is 
widely known that metastasis is not a random process and cancerous tumor 
cells that get into circulation don’t always metastasize to target organs. 
Researchers found that certain genes expressed by the tumor cells direct the 
metastasis of those cells to specific target organs11. Therefore, subsequent 
research must be done in order to identify those specific genes and their 
genetic pathways. 
The interleukin-33 (IL-33) gene encodes a newly identified pro-
inflammatory, signaling cytokine that is secreted by colon cancer cells and 
apoptotic cells. The secretion of the IL-33 cytokine provides a link between 
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inflammation and cancer and plays a major role in tumor cells’ resistance to 
apoptosis and chemoresistance in tumor cells. This indicated that the IL-33 
signaling pathway plays a crucial role in the pathogenesis of colon cancer5. 
IL-33 is also an alarmin secreted by necrotic cells upon trauma and infection, 
which is necessary for proper virus control in the immune system. Using 
microarray analysis, Dr. Pena’s laboratory identified IL-33 as the most 
highly secreted cytokine in the highly metastatic colon cancer cell line, 
CT26-FL3 as compared to the parental CT-26 cells.  In this study, we will 
test our hypothesis that the increased circulating levels of IL-33 in serum of 
tumor bearing mice will increase colorectal cancer metastasis to the liver. 
The importance of IL- 33 in colon carcinogenesis and immune system 
responses is a widely accepted concept, but also a highly under-researched 

















 In the United States, colorectal cancer is the third leading cause of 
cancer-related deaths in both men and women1. The pathogenesis of 
colorectal cancer begins with the development of polyps in the innermost 
colorectal lining and progresses to the final stage when metastasis occurs2.     
Metastasis is the spread of cancer cells to other organs, and has been shown 
to be organ specific rather than a random process.  Genes that direct tumor 
cells to target specific organs have been identified.  The primary tumor is 
thought to secrete molecules that promote the establishment of liver 
metastasis even before the arrival of cancer cells into this organ.   
 We have previously isolated a highly liver metastatic cell line, CT26-
FL3 by in vivo selection of CT26 cells in balb/c mice.  Microarray analyses 
showed that the CT26-FL3 cells expressed 34-fold higher levels of the 
Interleukin-33 (IL-33) cytokine as compared to the parental and less 
metastatic CT26 cells.  Over-expression of IL-33 was shown to potently 
promote tumor proliferation and metastasis to the liver5 indicating that IL-33 
plays a crucial role in the pathogenesis of colon cancer.  
 In this study, we will use C57Bl/6 mice and the murine colon cancer 
cell line, MC38, to increase circulating serum levels of IL-33 using a gene 
therapy approach by in vivo electroporation of a plasmid expressing IL-33, 
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pV1J-IL33.  We hypothesized that the increased secretion of IL-33 in MC38 
tumor cells will increase cell metastasis to the liver, and that increasing 
circulating levels of IL-33 in mice bearing MC38 tumors will be sufficient to 
enhance its ability to metastasize to the liver.  
 Here we report the construction of plasmids expressing IL-33 and 
verification of the expression of IL-33 from these plasmids in transfected 
cells by Western Blot analyses. We also discuss the introduction of pV1J-IL-
33 into C57Bl/6 mice by quadriceps injections and in vivo electroporation. 
Lastly, we report ELISA assays on mouse sera after splenic injections of 
MC38 tumor cells to determine the levels of secreted IL-33 and how long 
the IL-33 levels stayed up regulated after in vivo electroporation.   
 We concluded that the elevated serum levels of IL-33 increased tumor 


















Colorectal Cancer in Humans 
 
The pathogenesis of colorectal cancer occurs in five stages beginning 
with Stage 0 where cancer cells are developing only in the innermost 
colorectal lining.  Cell division and apoptosis are heavily regulated under 
normal conditions. Cancer cells have unchecked cell growth due to gene 
mutations.  These mutations can cause accelerated cell division rates and 
inhibit control mechanisms such as apoptosis and cell cycle arrest. 
Figure 1. A normal cell developing into a cancerous tumor. 
At Stage I, these cancerous cells collectively develop into a tumor on 
the inner colorectal walls, which then begin to extend deeper into the 
colorectal walls in Stage II. At Stage III, the cancerous cells begin to spread 
to the nearby lymph nodes and circulate through the blood stream. The final 
Stage IV of colorectal cancer is metastasis where the cancerous cells spread 
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to other parts of the body and invade other organs such as the liver and the 
lungs2. Unfortunately, colorectal cancer can develop without any symptoms 
and it usually isn’t detected until a primary tumor is found or metastasis has 
already occurred in the patient. Once metastasis has occurred, the five-year 
survival rate decreases to about 6%1. 
 
Figure 2. The pathogenesis of colorectal cancer from Stage 0 to Stage IV. 
Before cancerous colon cells metastasize to the liver, the primary 
tumor sends signals to the liver to recruit bone marrow derived cells that 
create a pre-metastatic niche. This pre-metastatic niche provides a fertile 
environment in the liver that promotes the growth of these cancerous colon 
tumor cells. Therefore, it is also important to identify the specific signals 
that are sent from the primary tumor to the target organ in order to prepare 
the pre-metastatic niche for the cancerous colorectal cells to home in. 
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Previous Work by Dr. Peña’s Lab 
 
Highly Metastatic Mouse Model. Dr. Peña’s lab created a mouse 
model of colon cancer using balb/c mice. They injected a parental line of 
CT26 colon cancer cells into the wall of the cecum of these balb/c mice in 
order to develop a primary tumor that spontaneously metastasizes to the liver. 
They found that only 8% of the balb/c mice injected with these CT26 cells 
had liver metastasis. They made a single cell suspension from these tumor 
cells, injected those cells into the cecum of the balb/c mice, and increased 
liver metastasis to 50%. They took the liver metastasis cells, grew them in 
culture, and injected those cells into the cecum. By repeating this procedure 
three times, the level of metastasis was increased to 90% and this new cell 
line was called the CT26-FL3 cell line. This created a CT26 cell line with a 







Figure 3. Development of CT26-FL3 cell line with 90% liver metastasis. 
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Elevated Circulating Levels of Interleukin-33. Microarray analysis shows 
all 44,000 genes expressed in a mouse on one slide, which allows you to 
analyze the expression levels of those genes at the same time. This allowed 
them to look at the genes that were highly expressed in the CT26 parental 
cell line versus the genes expressed in the highly metastatic CT26-FL3 cell 
line. After real time PCR was performed, it was observed that one of the 
most highly up-regulated genes was Interleukin-33 (IL-33). It was up-
regulated by the CT26-FL3 cells almost 34 fold when compared to the 
parental CT26 cells, while the protein expression levels remained the same 
between the two cell lines. This implies that the IL-33 is being sent out of 
the CT26-FL3 cells to affect other tissues and organs, which raises the 
question of what role the IL-33 gene is playing in metastasis and why it is 
being up-regulated and excreted from the cells.  
Study Objectives 
 
 The major objective of my project is to determine the role of 
Interleukin-33 (IL-33) in the metastasis of colorectal cancer to the liver. I 
will test the hypothesis that the elevated serum level of IL-33 is sufficient to 
enhance tumor growth and liver metastasis of tumors derived from MC38 
cells. Because IL-33 can also be secreted by hematopoietic cells in the tumor 
microenvironment that are involved in colorectal cancer metastasis, the 
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Materials and Methods 
 
 The cell lines used in the experiments were CT26 colon carcinoma 
cells and MC38 murine colon carcinoma cells.  The mice used were balb/c 
mice and C57Bl/6 mice. Splenic injections of CT26 cells and CT26-FL3 
cells were performed on balb/c mice. Splenic injections of MC38 cells were 
performed on C57Bl/6 mice. All procedures were approved by the 











Cloning IL-33 into pV1J Plasmid 
A plasmid expressing IL-33 was previously constructed in the Peña 
lab through DNA recombination. To start, restriction enzymes Kpn I and 
Eco RV digested the pCMV6-IL33 plasmid and the pV1J plasmid. Through 
gel electrophoresis, the restriction fragments were separated based on size 
leaving a pCMV6 plasmid fragment, a pV1J plasmid fragment, and an IL-33 
protein fragment. The pV1J and IL-33 fragments were ligated using T4 
DNA ligase and ligation buffer to form the pV1J-IL33 plasmid to be used in 
the remainder of the experiments.   
Plasmid Isolation Using Pure Yield Plasmid Miniprep System  
Two flasks were prepared, each containing 25mL of Luria broth and 
50μL of Kanamycin Marker. A sample of the pV1J-IL33 plasmid selected 
from colony 11 of the IL-33 stock plate was mixed into each flask. The 
flasks were stored in the 37°C incubator overnight.  The following day, the 
samples were aliquoted into 4 tubes and centrifuged for 5 minutes at 
3500rpm. Supernatants were discarded and 600μL of Molecular Biology 
Grade Water was added. The solutions were resuspended and aliquoted into 
4 1.5mL Eppendorf tubes for lysate preparation.  
 
 17 
100μL of Cell Lysis Buffer was added to the solution, the tubes were 
then inverted 15 times, and the solution processed for 5 minutes. 350μL of 
Neutralization Solution was added and the tubes were inverted until a 
homogenous yellow mixture was formed. The samples were centrifuged at 
13,000rpm for 3 minutes and the supernatants were transferred into the Pure 
Yield Minicolumns, which were then placed into a collection tube. The 
collection tubes were centrifuged for 1 minute at 13,000rpm and the excess 
flow through was discarded.  
To remove protein, RNA, and endotoxin contaminants from the 
purified plasmid DNA, 200μL of Endotoxin Removal Wash was added to 
the Minicolumns and they were centrifuged for 1 minute at 13,000rpm. 
400μL of Column Wash Solution was added to the Minicolumns and they 
were centrifuged for 1 minute at 13,000rpm.  
To elute the plasmids, the Minicolumns were transferred to 4 1.5mL 
Eppendorf tubes and 30μL of nuclease free water was added to the 
Minicolumns. They were processed for 1 minute and centrifuged at 
13,000rpm for 1 minute. The Minicolumns were discarded and the 
Eppendorf tubes were stored at -20°C.   
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Restriction Enzyme Digestion  
After the pV1J-IL33 plasmid DNA was purified, restriction enzyme 
digestion with 4 replicate samples was used to confirm the presence of the 
IL-33 protein in the pV1J plasmid. The following was added to each of the 4 
1.5mL Eppendorf tubes in order: 10.5μL of Molecular Biology Grade Water, 
1.5μL of NEB Buffer 3.1, 0.5μL of restriction enzyme EcoRV, 0.5μL of 
Bgl2, and 2μL of pV1J-IL33 plasmid. The Eppendorf tubes were incubated 
at 37°C for 2 hours. Gel electrophoresis was run for 25 minutes at 150V, 
which separated the pV1J plasmid and the IL-33 protein in the 4 replicate 
samples.  
Transient Transfection of pV1J-IL33 Plasmid into CT26 Cells and 
MC38 Cells Using Lipofectamine 2000 
Cell Culture. CT26 stock cells, MC38 stock cells, and cell media 
containing Dulbecco’s Modified Eagle Medium (DMEM), 10% Fetal 
Bovine Serum (FBS), and 1% Penicillin-Streptomycin were thawed at 37°C.  
4 cell plates were prepared under the hood – 2 plates for CT26 cells and 2 
plates for MC38 cells. 10mL of media and 1mL of cells were added to each 
plate, respectively. The cell plates were incubated at 37°C for 72 hours.  
 
 19 
After 72 hours, the cell cultures were split. The previously used cell 
media and Trypsin-EDTA were thawed at 37°C. Under the hood, 5mL of 
Trypsin-EDTA was added to each cell plate and processed for 5 minutes. 
After 5 minutes, 5mL of cell media was added to each plate and mixed 
thoroughly. Each of the 10mL cell solutions were added to 15mL tubes and 
centrifuged for 5 minutes at 2,000rpm. The supernatants were discarded, and 
5mL of cell media was used to resuspend the pellets. Onto 4 new cell plates, 
5mL of cell media was added along with 2.5mL of the resuspended cells 
solutions. The new cell plates were incubated at 37°C.  
After 96 hours, the cells were split again using the same procedure. 
The MC38 cells were split into a cell plate and 2 6-well plates. The CT26 
cells were split into a cell plate and 2 6-well plates. The cell plates contained 
10mL of cell media and 1 drop of cells. Each well of the 6-well plates 
contained 2.5mL of cell media and 250μL of cells. Each cell plate and 6-
well plate was thoroughly mixed and incubated at 37°C.   
Transient Transfection. The 6-well plates of MC38 Cells and CT26 
Cells were used for transient transfection. On each plate - 2 wells served as 
sample controls with no plasmid, 2 wells served as vector control samples 
with pV1J plasmid, and 2 wells served as experimental samples with pV1J-
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IL33 plasmid. Spectrophotometry determined the concentrations of the 
purified pV1J plasmid and the purified pV1J-IL33 plasmid to be used in the 
transient transfection.  
Under the hood, the old media was suctioned off and 2mL of cell 
media containing DMEM and 10% FBS was added to each well. 6 tubes 
were labeled as Control A, Control B, pV1J A, pV1J B, IL-33 A, and IL-33 
B. The Control A tube contained 400μL of DMEM. The pV1J A tube 
contained 400μL of DMEM and 18.1μL of pV1J vector. The IL-33 A tube 
contained 400μL of DMEM and 21.62μL of pV1J-IL33 plasmid. The 
Control B tube, the pV1J B tube, and the IL-33 B tube all contained 400μL 
of DMEM and 80μL of Lipofectamine 2000. After 5 minutes of processing, 
the A and B tubes of each respective sample type were combined. The 
combined control solution, the combined pV1J solution, and the combined 
pV1J-IL33 solution processed for 15 minutes. Each solution was evenly 
distributed and mixed into their respective wells of the 6-well plates and 
incubated for 72 hours at 37°C. 
Protein Isolation  
A 6-well plate from both the MC38 transfected cells and CT26 
transfected cells were used for protein isolation from these cell samples. 
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500μL of Trypsin was added to each well and processed for 5 minutes. After 
5 minutes, 500μL of media was added to each well and the 1mL solution 
from each well was aliquoted into 1.5mL Eppendorf tubes. The tubes were 
centrifuged for 5 minutes at 3,000rpm and the supernatants were removed. 
500μL of PBS was added to each Eppendorf tube, the tubes were centrifuged 
for 5 minutes at 3,000rpm, and the supernatants were discarded.  
100μL of Protein Extraction Buffer was added and mixed into each 
cell pellet. After 10 minutes of incubation on ice, the tubes were centrifuged 
for 40 minutes at 11,000rpm. The supernatants were collected into new 
Eppendorf tubes and the protein concentrations in the samples were 
determined using Gen5 Data Analysis Software.  The protein samples were 
stored in -80°C.  
Western Blot Analysis  
The intracellular levels of IL-33 in the CT26 cells transiently 
transfected with pV1J and pV1J-IL33 were measured using a Western 
Blotting technique. The isolated protein samples were mixed with 6X SDS 
and Molecular Biology Grade Water and heated for 10 minutes at 95°C. The 
proteins were separated through agarose gel electrophoresis at 150V for 60 
minutes. The proteins were then transferred to a nitrocellulose membrane at 
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100V for 100 minutes.  
The membrane was blocked for 1 hour with a 5% milk solution 
comprised of 2.5g of Bio-Rad Blotting Grade Blocker Nonfat dry milk and 
50mL of PBST. The MAB3626 anti-mIL-33 primary antibody was diluted 
1:500 with PBST and added to the membrane for overnight incubation at 
4°C. The membrane was washed 3 times for 10 minutes with PBST. The 
PAI-28636 Thermo goat anti-rat secondary antibody was diluted 1:2500 
with PBST and added to the membrane for 1 hour of incubation at room 
temperature. The membrane was washed 3 times for 10 minutes with PBST. 
500μL of each ECL Western Blot Detection reagent was mixed and added to 
the membrane for 2 minutes. Nitrocellulose membrane images were 
quantified using chemiluminescence. 
RNA Isolation Using Bio-Rad RNA Isolation Kit 
The two remaining 6-well plates from the MC38 transfected cells and 
CT26 transfected cells were used for RNA isolation from these cell samples. 
500μL of Trypsin was added to each well and processed for 5 minutes. After 
5 minutes, 500μL of media was added to each well and the 1mL solution 
from each well was aliquoted into 1.5mL Eppendorf tubes. The tubes were 
centrifuged for 5 minutes at 3,000rpm and the supernatants were removed. 
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500μL of PBS was added to each Eppendorf tube, the tubes were centrifuged 
for 5 minutes at 3,000rpm, and the supernatants were discarded.  
350μL of a TRK Lysis Buffer and BME mixture was added and 
mixed into each cell pellet. The cells were homogenized using a needle and 
syringe. 350μL of 70% ethanol solution was added to the tubes and mixed 
well. The solutions were poured through spin columns and centrifuged for 1 
minute at 10,000rpm and the flow through liquid was decanted. 500μL of 
Wash Buffer I was added to each spin column. The columns were 
centrifuged for 30 seconds at 10,000rpm and the flow through liquid was 
decanted. 500μL of Wash Buffer II was added to each spin column. The spin 
columns were centrifuged for 1 minute at 10,000rpm and the flow through 
liquid was decanted. The Wash Buffer II step was repeated. The spin 
columns were then centrifuged for 2 minutes at 10,000rpm and the flow-
through liquid was decanted. 
cDNA Preparation Using Bio-Rad iScript cDNA Synthesis Kit and    
Real-Time Polymerase Chain Reaction (RT-PCR) 
The spin columns from the RNA isolation procedure were then placed 
into blue RNA columns. 40μL of DEPC water was poured directly onto the 
white filters in the spin columns and the columns were centrifuged for 2 
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minutes at 10,000rpm. The RNA concentrations of the flow through liquid 
were determined using Gen5 Data Analysis Software. The RNA samples 
were then mixed with 4μL of 5x iScript Reaction Mix, 1.0μL of iScript 
Reverse Transcriptase, and Nuclease-Free water. Using a Thermocycler, the 
reaction mix was incubated for 5 minutes at 25°C, 30 minutes at 42°C, 5 
minutes at 85°C, then held at 4°C. The results were quantified using 











Intramuscular In Vivo Electroporation
 
Figure 5. In vivo electroporation on C57Bl/6 mice. 
To increase the serum levels of IL-33 in C57Bl/6 mice, intramuscular 
in vivo electroporation was performed using the pV1J-IL-33 plasmid 
purified under endotoxin free conditions. 
50μg of the plasmid was injected into the surgically exposed 
quadriceps muscle of C57Bl/6 mice, and then electrodes were used to apply 
8 pulses of 100 volts for 50 milliseconds each at the sight of injection, 
forcing the IL-33 plasmid DNA to be taken in by the muscle cells. The 
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muscles cells then expressed the IL-33 protein and secreted the protein into 
the bloodstream of the mice. Starting at 3 hours after electroporation, sera 
were collected by retro-orbital eye bleeding and then every 4 days up to 3 
weeks post-electroporation.  
Enzyme-Linked Immunosorbent Assay (ELISA) 
In a separate experiment, an RnD Systems Quantikine Mouse/Rat IL-
33 Enzyme-Linked Immunosorbent Assay (ELISA) was performed on the 
mouse sera to determine the levels of secreted IL-33 and how long the IL-33 
levels stay up regulated after in vivo electroporation. A microplate pre-
coated with an antibody for mouse/rat IL-33 was used for the assay. All sera 
samples and reagents were brought to room temperature. The mouse/rat IL-
33 control was reconstituted with 1.0mL of deionized water, and 20mL of 
the Wash Buffer Concentrate was diluted with 480mL of deionized water. 
The Substrate Solution was prepared 15 minutes prior to usage by mixing 
3.5mL of Color Reagent A with 3.5mL of Color Reagent B and protecting 
the solution from light. The mouse/rat Il-33 standard was reconstituted with 




50μL of Assay Diluent RD1-40, Standard, Control, and sera samples 
were added to the wells of the microplate and incubated for 2 hours at room 
temperature. Each well was aspirated and washed 5 times with 400μL of 
Wash Buffer. 100μL of mouse/rat IL-33 conjugate was added to each well 
and incubated for 2 hours at room temperature. Each well was aspirated and 
washed 5 times with 400μL of Wash Buffer. 100μL of substrate solution 
was added to each well and incubated for 30 minutes at room temperature 
protected from light. 100μL of stop solution was added to each well and 
mixed thoroughly. The optical density was determined with a microplate 
reader at 450nm, with wavelength correction at 570nm. All data analysis 
was conducted using Microsoft Excel.  
Splenic Injections and In Vivo Electroporation 
Based on the results of the previous intramuscular in vivo 
electroporation procedure, an injection of 50μg of plasmid produced the 
highest detected serum levels of IL-33 in C57Bl/6 mice. Using a sample of 
12 C57Bl/6 mice, 6 mice received a quadriceps muscle injection of 50μg of 
pV1J and 6 mice received a quadriceps muscle injection of 50μg of pV1J-
IL33. Following in vivo electroporation, approximately 200,000 MC38 
tumor cells were injected into the spleens of the C57Bl/6 mice. To determine 
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the effect of the increased serum levels of IL-33 on liver metastasis of MC38 
cells, the tumor cells injected into the spleen were allowed to grow and 
metastasize to the liver for 21 days. After 21 days, the C57Bl/6 mice were 
humanely sacrificed and the spleens and livers were harvested. The tumor 
growth and metastasis to the liver was determined by measuring the weights 



























Figure 6.  Map of  pCMV6-IL33 plasmid 
which was the source of the IL-33 gene. 
 
Figure 7.  Map of the pV1J vector 
wherein the IL-33 gene was cloned into.   
 
Figure 8.  Agarose Gel electrophoresis of digested plasmids.  pCMV6-IL33 and 
pV1J plasmids were digested with Kpn1 and EcoRV restriction enzymes.  The 
digested fragments were separated by electrophoresis in a 0.8% agarose gel.  Lane 1: 1 
kb ladder, Lane 3: Digested pV1J plasmid, Lane 5: Digested pCMV6-IL33 Plasmid, 
Lane 7: 100 bp ladder.  The fragments highlighted in the red squares were purified and 





































Figure 9: pV1J-IL33 Vector 
 
 
Figure 9.  Map of the pV1J-IL33 plasmid that was constructed.  This plasmid was 
used for in vitro transfection and in vivo electroporation experiments. 
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Figure 10. The pV1J and pV1L-IL33 plasmids were transfected into CT26 
and MC38 colon cancer cell lines to determine expression of IL-33.  Real 
time PCR analysis was used to determine the mRNA transcription levels of 
IL-33 in CT26 and MC38 derived cell lines. 
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IL-33 protein levels in CT26 cells transiently transfected with pV1J-









Figure 11. IL-33 protein expression in CT26 cells transiently transfected 
with pv1J and pV1J-IL33.  (IL33: pV1J-IL33 Vector, V: pV1J Vector, 
Control: non-transfected CT26 cells)  
 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
 
 
Figure 12. Concentration of IL-33 in the serum of C57Bl/6 mice following 
in vivo electroporation. Serum levels in mice injected with MC38 pV1J-
IL33 cells were highest on Day 1 at 443 pg/μL and second highest on Day 4 

















































Assessment of the Rate of Metastasis in C57Bl/6 Mice 
Figure 13. Primary tumors in the spleen and secondary tumors in the liver of 
C57Bl/6 mice injected with MC38 tumor cells and 50μg pV1J plasmid.  
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Figure 14. Primary tumors in the spleen and secondary tumors in the liver of 






































Figure 15. Assessment of the rate of metastasis in C57Bl/6 mice by 
measuring liver weights. The average liver weight for MC38 pV1J C57Bl/6 
mice was 1.33 grams and the average liver weight for MC38 pV1J-IL33 







































Figure 16. Assessment of the rate of metastasis in C57Bl/6 mice by 
measuring spleen weights. The average spleen weight for MC38 pV1J 
C57Bl/6 mice was 0.161 grams and the average spleen weight for MC38 




Discussion and Conclusions 
  
Colorectal cancer metastasis is a multistep process that oftentimes 
develops without any detectable symptoms prior to the fatal stages of the 
disease. Although colorectal cancer is the third leading cause of cancer-
related deaths in the United States, the mechanisms involving the 
progression to the lethal stages of colorectal cancer where cancer cells have 
invaded the liver and other organs remains under-researched. It has been 
found by the Peña lab that there are particular biomarkers that are up 
regulated in colorectal cancer cells that could potentially represent 
significant aspects of the transition to the metastatic stages of the disease. In 
previous studies, a highly liver metastatic CT26-FL3 cell line showed 
extremely elevated levels of the IL-33 protein. Identifying biomarkers such 
as IL-33 can increase early detection of colorectal cancer and improve 
diagnostic and therapeutic procedures. 
In order to study the role of IL-33 on the metastasis of colorectal 
cancer to the liver, several in vitro and in vivo experiments were performed. 
The first experiment involved cloning IL-33 into the pV1J plasmid to create 
the pV1J-IL33 plasmid to be used for the remainder of the study procedures.  
The pCMV6-IL33 plasmid and pV1J plasmid were purified and digested 
with restriction enzymes Kpn I and Eco RV. Gel electrophoresis confirmed 
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the presence of equally cut plasmids and the excised IL-33.  Ligation of the 
digested pV1J plasmid and the excised IL-33 created the pV1J-IL33 vector 
used in the subsequent experimental procedures. 
To create a colorectal cancer cell line containing the IL-33 protein, the 
pV1J and pV1J-IL33 plasmids were transiently transfected into CT26 cells 
and MC38 cells. To confirm the presence of the IL-33 in these cell lines, the 
protein and RNA were isolated. Western Blot analysis of the proteins 
isolated from the CT26 cells transiently transfected with IL-33 showed 
increased IL-33 protein expression in the cells containing pV1J and pV1J-
IL33 compared to the control cells with no plasmid. The results of the 
Western Blot analysis of the MC38 cell line did not show visible results.  To 
further confirm the up regulated expression of IL-33 in the CT26 and MC38 
cell lines transiently transfected with IL-33 RNA was isolated, cDNA was 
synthesized, and RT-PCR was performed.  After quantification using Excel, 
the relative mRNA expression levels in the CT26 cells transiently 
transfected with the pV1J-IL33 plasmid were shown 5400-fold when 
compared to the cells containing no plasmid and the pV1J vector. Similar 
results were seen in the MC38 cell line, where the cells transiently 
transfected with pV1J-IL33 expressed mRNA 7000-fold when compared to 
the MC38 cells containing no plasmid and the pV1J vector. Although the IL-
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33 protein was not over-expressed drastically in the cells containing pV1J 
and pV1J-IL33, the IL-33 mRNA expression levels were extremely over-
expressed in the cells containing pV1J-IL33. The over-expression of IL-33 
mRNA levels did not correlate to the protein over-expression of IL-33, 
which indicates that IL-33 protein is being immediately secreted from the 
cells after synthesis. To confirm this hypothesis, the intracellular levels of 
the IL-33 protein in the cell media samples should have been analyzed 
through Western Blotting techniques. 
After confirming that the MC38 transiently transfected cells 
containing the pV1J-IL33 had the highest up regulated levels of IL-33, 
subsequent in vivo experiments were performed to determine if muscle cells 
in C57Bl/6 mice would uptake the MC38 transiently transfected cells and 
secrete the IL-33 protein into the sera of the C57Bl/6 mice. Intramuscular in 
vivo electroporation was performed using the pV1J-IL33 plasmid in order to 
increase the serum levels of IL-33 in C57Bl/6 mice. 50μg of the plasmid was 
injected into the quadriceps of the C57Bl/6 mice and electrodes applied 
pulses of electricity to the injection site to force the uptake of the plasmid 
DNA into the muscle cells. These cells then expressed the IL-33 protein and 
secreted the protein into the bloodstream of the C57Bl/6 mice. Blood sera 
were collected through retro-orbital bleeding prior to any experimental 
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procedures. Blood sera were also collected post-electroporation, which was 
performed on days 1, 4, 10, and 15. The concentration of IL-33 in C57Bl/6 
mice sera was extremely up regulated following electroporation on day 1 
and day 4 in mice receiving the pv1J-IL33 plasmid. The sera levels were 
normal on day 10 and day 15. Since the IL-33 protein is an alarmin secreted 
by necrotic cells upon trauma and infection, the sera levels of IL33 2 weeks 
post-injection were mainly due to the invasive procedure. If the in vivo 
electroporations were carried out for an additional 3-4 weeks, then the 
observed sera levels of IL-33 would be produced by the injected pv1J-IL33 
MC38 cells.  
After confirming that the sera levels of circulating IL-33 protein in 
C57Bl/6 mice increased following in vivo electroporation, splenic injections 
were performed to analyze the effects of the elevated circulating levels of 
IL-33 on the metastasis of colorectal cancer cells to the liver. Following in 
vivo electroporation, approximately 200,000 MC38 tumor cells were 
injected into the spleens of the C57Bl/6 mice. Splenic injection of MC38 
tumor cells facilitates rapid liver metastasis because of the splenic vein that 
is directly connected to the portal vein of the liver. The tumor cells injected 
into the spleen were allowed to grow under conditions of high circulating 
IL-33 protein and metastasized to the liver for a total of 21 days. After 
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humanely sacrificing the mice, the primary tumors in the spleen and the 
secondary tumors in the liver were examined and the organs were weighed. 
Quantification of the data through Excel showed that the average weight of 
the spleens in C57Bl/6 mice receiving the pV1J-IL33 plasmid was almost 3 
times the average weight of the spleens in mice receiving the pV1J plasmid. 
A similar trend was seen in the average weight of the livers of C57Bl/6 mice, 
on a less extreme level. Images of the spleens and livers showed more 
visible tumors in both organs of the C57Bl/6 mice receiving the pV1J-IL33 
plasmid than in the mice receiving pV1J. 
Due to these findings, MC38 cells transiently transfected with pV1J-
IL33 plasmids have increased IL-33 mRNA and protein expression. 
Subsequently, the injection of pV1J-IL33 MC38 cells into the quadriceps of 
C57Bl/6 mice and in vivo electroporation increases circulating sera levels of 
the IL-33 protein. The increased circulating levels of IL-33 protein were 
primarily due to the alarmin properties of the IL-33 protein following the 
injection and in vivo electroporation. Elevated circulating levels of IL-33 in 
addition to splenic injections of MC38 tumor cells can increase the 
metastasis of primary tumor cells to the liver to form secondary tumors.  
Due to the limited experimental timeframe, there are several future 
experiments that can stem directly from these primary conclusions. The 
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protein expression levels can be further analyzed to determine why the 
extremely high mRNA expression levels don’t manifest in the protein 
expression levels. The cell media protein expression levels can also be 
determined through Western Blotting techniques to confirm the excretion of 
IL-33 immediately following its translation. Furthermore, the experiments 
can be repeated with a larger sample size of mice in order to create 
statistically significant results. If carried out for a increased time span, 
researchers will be able to determine that the injected pV1J-IL33 MC38 cells 
caused the increased circulating sera levels of IL-33 rather than the alarmins 
produced following the surgical procedure. Also, an ELISA performed on 
the C57Bl/6 mice sera following splenic injections of MC38 cells would 
determine if the IL-33 protein levels are still elevated during tumor growth 
and metastasis to the liver.  Additionally, in vivo experiments using balb/c 
mice and CT26 cells would also reconfirm the effects of the increased 
circulating levels of IL-33 on the metastasis of colorectal cancer. By 
deliberately increasing the IL-33 mRNA and protein expression levels and 
increasing the levels of MC38 colorectal cancer cells in C57Bl/6 mice, liver 
metastasis was heavily induced and the primary results supported the 
hypothesis. Collectively, the experiments performed in addition to the future 
directions will help to further understand the effects of certain biomarkers in 
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colorectal cancer cells in patients in order to improve the detection time and 
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